Login to Your Account

Other News To Note

Wednesday, August 28, 2013
• Carolus Therapeutics Inc., of San Diego, and The Alpha-1 Project Inc. (TAP), a wholly owned subsidiary of the Alpha-1 Foundation, are collaborating to characterize human biological samples for the presence of the target, RANTES:PF4 heterodimer, a soluble protein complex that is secreted by activated platelets and implicated in many inflammation-related diseases, including genetic emphysema and chronic obstructive pulmonary disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription